CClinicalTrials.gg
CompletedNCT05495555Updated Mar 11, 2025Results posted

The Cutting Efficiency of Hybrid Tips in Different Grades of Cataract

An observational study in Cataract, sponsored by Cataract and Laser Institute of Southern Oregon. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Cataract and Laser Institute of Southern Oregon · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
51
Ages
50 Years and older
Sex
All
01

Study summary

The objective is to assess the efficiency (as measured by phaco time, aspiration time, and fluid use) of the hybrid tip in removing cataract grade 3 \& 4 in high and low intraocular pressure (IOP) settings.

Read the detailed description

This study is a Single site, single-masked, randomized, prospective, observational study of the efficiency of the hybrid tip in removing cataract grade 3 \& 4 in high and low intraocular pressure (IOP) settings. Subjects will be assessed pre-operatively, operatively and at 1 day and 1 week post-operatively. Clinical evaluations will include measurement of visual acuity, central corneal thickness, IOP, visual analog pain scale, and slit lamp examination.

02

Conditions studied

  • Cataract

Browse trials for

03

In context

Cataract

1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.

This study's enrollment of 51 is below the median of 81 across 484 observational studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Cataract and Laser Institute of Southern Oregon is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Eligible test subjects will be 50 years of age or older and who are eligible to undergo sequential bilateral uncomplicated cataract surgery.

Eligibility criteria

Subjects are eligible for the study if they meet the following criteria:

Note: Ocular criteria must be met in both eyes.

  • Be eligible to undergo sequential bilateral uncomplicated cataract surgery
  • Grade 3 or 4 cataract (PNS or LOCS III)
  • Undergo uneventful cataract surgery
  • Gender: Males and Females.
  • Age: 50 or older.
  • Willing and able to provide written informed consent for participation in the study.
  • Willing and able to comply with scheduled visits and other study procedures.

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

  • Patient under 50 years of age
  • Unable to complete sequential bilateral cataract surgery in both eyes by the same surgeon (JS)
  • Patient cataract surgery complicated by posterior capsular tear
  • Any disease state deemed by PI that increases risk of complicated cataract surgery (ie Pseudoexfoliation syndrome, zonular dehiscence, history of eye trauma. RA, prior refractive surgery, etc)

The principal investigator reserves the right to declare a patient ineligible or non- evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
51 participants (actual)
Patient registry
No

Groups and cohorts

  • High IOP setting

    Cataract removal with high IOP setting

    Device: INTREPID® Hybrid tip

  • Low IOP setting

    Cataract removal with low IOP setting

    Device: INTREPID® Hybrid tip

Interventions

  • DeviceINTREPID® Hybrid tip

    INTREPID® Hybrid tip for cataract removal

06

What researchers measure

Primary outcomes

  1. Phaco Time

    Time frame: Day 0 (surgical visit)

  2. Aspiration Time

    Time frame: Day 0 (surgical visit)

  3. Fluid Use

    Time frame: Day 0 (surgical visit)

Secondary outcomes

  1. Central Corneal Thickness Change From Baseline

    Time frame: baseline and 1 week postoperative

Other outcomes

  1. Cumulative Dissipated Energy

    This will measure the the amount of ultrasound energy used during cataract removal

    Time frame: Day 0 (surgical visit)

07

Results

Posted Mar 11, 2025

Participant flow

Participant flow — Overall Study
MilestoneHigh IOP SettingLow IOP Setting
Started5151
Completed5151
Not completed00

Outcome measures

PrimaryPhaco Time
Time frame:
Day 0 (surgical visit)
Reported as:
Mean · seconds
Phaco Time
secondsHigh IOP SettingLow IOP Setting
Phaco Time41.6 ± 1041.8 ± 10.2
PrimaryAspiration Time
Time frame:
Day 0 (surgical visit)
Reported as:
Mean · seconds
Aspiration Time
secondsHigh IOP SettingLow IOP Setting
Aspiration Time101.7 ± 27.2106.7 ± 25.3
PrimaryFluid Use
Time frame:
Day 0 (surgical visit)
Reported as:
Mean · mL
Fluid Use
mLHigh IOP SettingLow IOP Setting
Fluid Use41.6 ± 9.040.2 ± 7.8
SecondaryCentral Corneal Thickness Change From Baseline
Time frame:
baseline and 1 week postoperative
Reported as:
Mean · µm
Central Corneal Thickness Change From Baseline
µmHigh IOP SettingLow IOP Setting
Central Corneal Thickness Change From Baseline5.4 ± 5.18.1 ± 8.9
Other pre-specifiedCumulative Dissipated Energy

This will measure the the amount of ultrasound energy used during cataract removal

Time frame:
Day 0 (surgical visit)
Reported as:
Mean · µJ
Cumulative Dissipated Energy
µJHigh IOP SettingLow IOP Setting
Cumulative Dissipated Energy8.7 ± 3.18.6 ± 3.4

Adverse events

Collected over 1 week. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High IOP Setting0/51 (0%)0/51 (0%)3/51 (5.9%)
Low IOP Setting0/51 (0%)0/51 (0%)3/51 (5.9%)
Most frequent other events
Most frequent other events
EventHigh IOP SettingLow IOP Setting
Elevated IOPEye disorders3/513/51

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean75.8 ± 6.7
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female31
Male20
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)All Participants
Region of Enrollment
Region of Enrollment(participants)All Participants
United States51
08

Study locations

1 site
  • Cataract & Laser Institute
    Medford, Oregon 97504, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Feb 21, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05495555
Lead sponsor
Cataract and Laser Institute of Southern Oregon
Collaborators
Sengi
Responsible party
Sponsor
First posted
Aug 10, 2022
Start date
Aug 3, 2022
Primary completion
Feb 7, 2024
Completion
Feb 7, 2024
Results posted
Mar 11, 2025
Last update
Mar 11, 2025

Study contacts

Justin Spaulding, DO
principal investigator · Cataract & Laser Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion